Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis 2017-02-14 06:27
Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs 2016-06-09 18:45
Patient-reported Outcomes across Phase 3 studies of Baricitinib demonstrate Statistically Significant Improvements in Physical Function and Quality of Life Symptoms in Patients with Rheumatoid Arthritis (RA) 2016-06-09 18:45
1